INTRODUCTION:
DEFA1A3
encodes human neutrophil peptides (HNPs) 1–3 and has multiple copy number variations (CNVs). HNPs are associated with innate immunity. Ulcerative colitis (UC), a chronic inflammatory gastrointestinal disorder, is a life-threatening condition, and predictive markers of UC severity are needed. This study investigated the relationship between
DEFA1A3
CNV and UC severity.
METHODS:
This study enrolled 165 patients with UC. The relationship between
DEFA1A3
CNV and disease severity was analyzed based on Mayo score, patient characteristics, and treatment methods. In addition, serum and stimulated neutrophil-derived HNP concentrations were also measured in patients with high and low
DEFA1A3
CNV.
RESULTS:
DEFA1A3
CNV was significantly correlated with Mayo score and white blood cell count (
R
= 0.46,
P
< 0.0001;
R
= 0.29,
P
= 0.003, respectively), and only high copy numbers of
DEFA1A3
were independent factors for severe UC (
P
< 0.001, odds ratio: 1.88, 95% confidence interval, 1.34–2.61). The number of severe UC patients with high
DEFA1A3
CNV was significantly greater than those with low CNV. We confirmed the associations between
DEFA1A3
and UC severity using a validation cohort. In addition, the HNP concentration in high-copy number patients was significantly higher after neutrophil stimulation than that in low-copy number patients.
DISCUSSION:
This study demonstrated that there is a correlation between
DEFA1A3
copy number and severity in patients with UC. In addition, neutrophils from UC patients with higher
DEFA1A3
CNV had high reactivity of secretion of HNPs after stimulation.
DEFA1A3
CNV may be a novel severity marker and a potential therapeutic target for UC.